ECONOMIC PROSPECT ANALYSIS

Abbott Laboratories (ABT)

Forward-looking competitive assessment — compiled by Gemini 3.1

Moderate Prospect

Diversified medtech/diagnostics company. FreeStyle Libre CGM is the growth star. Post-COVID diagnostics revenue normalization creates tough comps.

View DCF Intrinsic Value Analysis →

Competitive Momentum

22/35

Moat Durability

24/35

Sentiment & Catalysts

20/30

🚀 Key Catalysts

Libre 3 with continuous ketone monitoring expanding TAM beyond diabetes to weight management
Structural heart devices growing 15%+ in a large addressable market
Medical device innovation pipeline across multiple high-growth categories

⚠️ Key Risks

FreeStyle Libre growth decelerating as diabetes CGM market matures
Nutrition segment recovering slowly from Sturgis plant issues
Diagnostic revenue normalizing post-COVID

Methodology

Score is based on three pillars: Competitive Momentum (0-35), Moat Durability (0-35), and Sentiment & Catalysts (0-30), totaling 0-100. Each pillar is broken into individually scored factors with transparent rationale. Data sources include FY2025 10-K filings, analyst consensus estimates, news sentiment analysis, and competitive landscape assessment. The score is forward-looking and represents economic prospect over a 2-3 year horizon.

Disclaimer: This economic prospect score is for educational purposes only. It is generated by an AI model (Gemini 3.1) based on publicly available data and may not reflect all material factors. This does not constitute investment advice. Always conduct your own due diligence.